These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 22262882)

  • 21. The effects of methylphenidate on neural systems of attention in attention deficit hyperactivity disorder.
    Shafritz KM; Marchione KE; Gore JC; Shaywitz SE; Shaywitz BA
    Am J Psychiatry; 2004 Nov; 161(11):1990-7. PubMed ID: 15514398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.
    Chronis-Tuscano A; Seymour KE; Stein MA; Jones HA; Jiles CD; Rooney ME; Conlon CJ; Efron LA; Wagner SA; Pian J; Robb AS
    J Clin Psychiatry; 2008 Dec; 69(12):1938-47. PubMed ID: 19192455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Age-Dependent Effects of Methylphenidate on the Human Dopaminergic System in Young vs Adult Patients With Attention-Deficit/Hyperactivity Disorder: A Randomized Clinical Trial.
    Schrantee A; Tamminga HG; Bouziane C; Bottelier MA; Bron EE; Mutsaerts HJ; Zwinderman AH; Groote IR; Rombouts SA; Lindauer RJ; Klein S; Niessen WJ; Opmeer BC; Boer F; Lucassen PJ; Andersen SL; Geurts HM; Reneman L
    JAMA Psychiatry; 2016 Sep; 73(9):955-62. PubMed ID: 27487479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.
    Stein MA; Sarampote CS; Waldman ID; Robb AS; Conlon C; Pearl PL; Black DO; Seymour KE; Newcorn JH
    Pediatrics; 2003 Nov; 112(5):e404. PubMed ID: 14595084
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of a single-dose methylphenidate challenge on resting-state functional connectivity in stimulant-treatment naive children and adults with ADHD.
    Kaiser A; Broeder C; Cohen JR; Douw L; Reneman L; Schrantee A
    Hum Brain Mapp; 2022 Oct; 43(15):4664-4675. PubMed ID: 35781371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder.
    Wilens TE
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S46-53. PubMed ID: 18480677
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term effects of stimulant exposure on cerebral blood flow response to methylphenidate and behavior in attention-deficit hyperactivity disorder.
    Schrantee A; Bouziane C; Bron EE; Klein S; Bottelier MA; Kooij JJS; Rombouts SARB; Reneman L
    Brain Imaging Behav; 2018 Apr; 12(2):402-410. PubMed ID: 28321605
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methylphenidate for children and adolescents with autism spectrum disorder.
    Sturman N; Deckx L; van Driel ML
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011144. PubMed ID: 29159857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regional cerebral blood flow in children with attention deficit hyperactivity disorder: comparison before and after methylphenidate treatment.
    Lee JS; Kim BN; Kang E; Lee DS; Kim YK; Chung JK; Lee MC; Cho SC
    Hum Brain Mapp; 2005 Mar; 24(3):157-64. PubMed ID: 15486990
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Counting Stroop Functional Magnetic Resonance Imaging Study on the Effects of ORADUR-Methylphenidate in Drug-Naive Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Chou TL; Hsieh CY; Gau SS
    J Child Adolesc Psychopharmacol; 2022 Nov; 32(9):467-475. PubMed ID: 36251766
    [No Abstract]   [Full Text] [Related]  

  • 32. Long-term Effects of Multimodal Treatment on Adult Attention-Deficit/Hyperactivity Disorder Symptoms: Follow-up Analysis of the COMPAS Trial.
    Lam AP; Matthies S; Graf E; Colla M; Jacob C; Sobanski E; Alm B; Rösler M; Retz W; Retz-Junginger P; Kis B; Abdel-Hamid M; Müller HHO; Lücke C; Huss M; Jans T; Berger M; Tebartz van Elst L; Philipsen A;
    JAMA Netw Open; 2019 May; 2(5):e194980. PubMed ID: 31150084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delay Aversion and Executive Functioning in Adults With Attention-Deficit/Hyperactivity Disorder: Before and After Stimulant Treatment.
    Low AM; le Sommer J; Vangkilde S; Fagerlund B; Glenthøj B; Sonuga-Barke E; Habekost T; Jepsen JRM
    Int J Neuropsychopharmacol; 2018 Nov; 21(11):997-1006. PubMed ID: 30124878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Supervised off-label prescribing of methylphenidate in adult ADHD].
    Carton L; Dondaine T; Deheul S; Marquié C; Brigadeau F; Amad A; Devos D; Danel T; Bordet R; Cottencin O; Gautier S; Ménard O
    Encephale; 2019 Feb; 45(1):74-81. PubMed ID: 30122296
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic imaging study with [Tc-
    Akay AP; Kaya GÇ; Kose S; Yazıcıoğlu ÇE; Erkuran HÖ; Güney SA; Oğuz K; Keskin D; Baykara B; Emiroğlu Nİ; Eren MŞ; Kızıldağ S; Ertay T; Özsoylu D; Miral S; Durak H; Gönül AS; Rohde LA
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Aug; 86():294-300. PubMed ID: 29684537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stimulant drugs trigger transient volumetric changes in the human ventral striatum.
    Hoekzema E; Carmona S; Ramos-Quiroga JA; Canals C; Moreno A; Richarte Fernández V; Picado M; Bosch R; Duñó L; Soliva JC; Rovira M; Bulbena A; Tobeña A; Casas M; Vilarroya O
    Brain Struct Funct; 2014 Jan; 219(1):23-34. PubMed ID: 23184398
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors of placebo response in adults with attention-deficit/hyperactivity disorder: data from 2 randomized trials of osmotic-release oral system methylphenidate.
    Buitelaar JK; Sobanski E; Stieglitz RD; Dejonckheere J; Waechter S; Schäuble B
    J Clin Psychiatry; 2012 Aug; 73(8):1097-102. PubMed ID: 22780962
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Methylphenidate down-regulates the dopamine receptor and transporter system in children with attention deficit hyperkinetic disorder (ADHD).
    Vles JS; Feron FJ; Hendriksen JG; Jolles J; van Kroonenburgh MJ; Weber WE
    Neuropediatrics; 2003 Apr; 34(2):77-80. PubMed ID: 12776228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating dopamine reward pathway in ADHD: clinical implications.
    Volkow ND; Wang GJ; Kollins SH; Wigal TL; Newcorn JH; Telang F; Fowler JS; Zhu W; Logan J; Ma Y; Pradhan K; Wong C; Swanson JM
    JAMA; 2009 Sep; 302(10):1084-91. PubMed ID: 19738093
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Biederman J; Mick E; Surman C; Doyle R; Hammerness P; Harpold T; Dunkel S; Dougherty M; Aleardi M; Spencer T
    Biol Psychiatry; 2006 May; 59(9):829-35. PubMed ID: 16373066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.